Oppenheimer Maintains ConforMIS Inc to Outperform with Price Target $13.00

Brokerage firm Oppenheimer Maintains its rating on ConforMIS Inc(NASDAQ:CFMS). In a research note issued to the investors, the brokerage major Raises the price-target to $13.00 per share. The shares have been rated Outperform. The rating by Oppenheimer was issued on Aug 9, 2016.

In a different note, On May 13, 2016, JP Morgan said it Downgrades its rating on ConforMIS Inc. In the research note, the firm Lowers the price-target to $18.00 per share. The shares have been rated ‘Neutral’ by the firm. On May 13, 2016, Wells Fargo said it Downgrades its rating on ConforMIS Inc. The shares have been rated ‘Market Perform’ by the firm. On May 13, 2016, Deutsche Bank said it Maintains its rating on ConforMIS Inc. In the research note, the firm Lowers the price-target to $26.00 per share. The shares have been rated ‘Buy’ by the firm.

ConforMIS Inc (CFMS) shares turned negative on Wednesdays trading session with the shares closing down -0.24 points or -2.78% at a volume of 2,43,401. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $8.75. The peak price level was also seen at $8.75 while the days lowest was $8.38. Finally the shares closed at $8.4. The 52-week high of the shares is $23.6173 while the 52-week low is $4.8. According to the latest information available, the market cap of the company is $354 M.

ConforMIS Inc(CFMS) last announced its earnings results on Aug 8, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $19.33M. Analysts had an estimated revenue of $18.02M. Earnings per share were $-0.34. Analysts had estimated an EPS of $-0.35.

ConforMIS Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop manufacture and sell joint replacement implants that are individually sized and shaped to fit each patient’s anatomy. It is engaged in offering a line of customized knee implants designed to restore the natural shape of a patient’s knee. The Company has sold over 30000 knee implants in the United States and Europe. It also launched iTotal PS the Company’s posterior-stabilized total knee replacement implant which addresses the largest segment of the knee replacement market. The Company’s products are available in the United States Germany and the United Kingdom. Its products are offered to orthopedic surgeons hospitals and other medical facilities and patients. The Company’s iFit technology platform includes three elements: iFit Design iFit Printing and iFit Just-in-Time Delivery.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *